Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis

Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors

The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health

Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema

The company announced positive topline data from the Phase 3 ADorable-1 trial

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors

Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts